These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8099964)

  • 21. Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats.
    Kase Y; Hayakawa T; Togashi Y; Kamataki T
    Jpn J Pharmacol; 1997 Dec; 75(4):399-405. PubMed ID: 9469646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.
    Matsuzaki T; Yokokura T; Mutai M; Tsuruo T
    Cancer Chemother Pharmacol; 1988; 21(4):308-12. PubMed ID: 3370738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA topoisomerase I changes the mode of interaction between camptothecin drugs and DNA as probed by UV-resonance Raman spectroscopy.
    Feofanov AV; Baranov AV; Fleury F; Riou JF; Nabiev IR; Manfait M
    FEBS Lett; 1996 Nov; 396(2-3):289-92. PubMed ID: 8915005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
    Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
    Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comment on a published paper. The adverse cholinergic effects of the chemotherapeutic agent irinotecan (CPT-11) were unlikely to be mediated by the inhibition of acetylcholinesterase (AChE).
    Dodds HM; Rivory LP
    Br J Pharmacol; 2001 Sep; 134(2):448-50. PubMed ID: 11564665
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
    Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
    Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
    Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
    Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicity of camptothecin (NSC-100880).
    Schaeppi U; Fleischman RW; Cooney DA
    Cancer Chemother Rep 3; 1974 Sep; 5(1):25-36. PubMed ID: 4213507
    [No Abstract]   [Full Text] [Related]  

  • 30. Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour.
    Xue H; Le Roy S; Sawyer MB; Field CJ; Dieleman LA; Baracos VE
    Br J Nutr; 2009 Aug; 102(3):434-42. PubMed ID: 19250573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents.
    Chowbay B; Sharma A; Zhou QY; Cheung YB; Lee EJ
    Oncol Rep; 2003; 10(3):745-51. PubMed ID: 12684653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Lavelle F; Bissery MC; André S; Roquet F; Riou JF
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
    Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
    Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor potential of a novel camptothecin derivative, ZBH-ZM-06.
    Wu D; Zhao DW; Li YQ; Shi WG; Yin QL; Tu ZK; Yu YY; Zhong BH; Yu H; Bao WG
    Oncol Rep; 2018 Feb; 39(2):871-879. PubMed ID: 29251321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonlinear pharmacokinetics of CPT-11 in rats.
    Kaneda N; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1721-5. PubMed ID: 2306726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.
    Morton CL; Wadkins RM; Danks MK; Potter PM
    Cancer Res; 1999 Apr; 59(7):1458-63. PubMed ID: 10197614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.